Amgen, AstraZeneca plan 2015 brodalumab filings on third Phase III success
This article was originally published in Scrip
Amgen plans to seek regulatory approvals for the psoriasis treatment brodalumab in 2015 now that the company and its partner AstraZeneca have reported success in a third Phase III clinical trial – the biologic's second late-stage victory over Johnson & Johnson's Stelara (ustekinumab).
You may also be interested in...
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.
Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.
Private Company Edition: Atea and Phlow receive big money for big COVID-19 problems – treatments and manufacturing capacity. Also, Cowen raises a $493m fund and antifungal developer Amplyx increases series C round to $90m, among other recent VC deals.